Chinese contract drug manufacturers, such as WuXi AppTec and WuXi Biologics, are currently enjoying strong order backlogs that promise stable earnings through 2027. However, analysts caution that the longer-term outlook is less certain due to a trend among US pharmaceutical companies to reshore their production and realign their supply chains in response to escalating tensions between the US and China. This shift could significantly impact the reliance on Chinese manufacturers, which have historically provided contract manufacturing services to western pharmaceutical firms.

Cui Cui, who leads healthcare research at Jefferies, noted that while earnings visibility for 2026 and 2027 remains robust due to pre-existing orders, there is growing concern over the sustainability of order growth beyond that period. As major US firms ramp up their manufacturing capabilities to bring operations back onshore around 2028-2029, this could diminish the demand for outsourcing in China. The trend reflects broader geopolitical shifts and a reassessment of supply chain strategies by US firms, motivated by both economic and national security considerations.

The implications for China's pharmaceutical sector are significant, as a decrease in demand for contract manufacturing could jeopardize the financial health of numerous companies that have thrived on these partnerships. As the US reshoring drive progresses, it highlights the challenges posed by international trade dynamics and forces Chinese firms to navigate an increasingly competitive and uncertain landscape that could reshape the future of their operations in the global pharmaceutical market.